Erasca Inc (ERAS)vsModerna Inc (MRNA)
ERAS
Erasca Inc
$15.88
-0.94%
HEALTHCARE · Cap: $6.25B
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
ERAS leads profitability with a 0.0% profit margin vs -141.4%. ERAS earns a higher WallStSmart Score of 25/100 (F).
ERAS
Avoid25
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ERAS.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Trading at 13.7x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ERAS
The strongest argument for ERAS centers on Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ERAS
The primary concerns for ERAS are Price/Book, Revenue Growth, EPS Growth.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ERAS profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
ERAS generates stronger free cash flow (-27M), providing more financial flexibility.
Bottom Line
ERAS scores higher overall (25/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Erasca Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Erasca Inc. is a pioneering biopharmaceutical firm specializing in the development of targeted therapies for genetically defined cancers, aiming to meet significant unmet needs in oncology. Utilizing its proprietary drug discovery platform that merges advanced genomics with precision medicine, the company is committed to creating treatments that directly target the mutations responsible for cancer progression. Erasca boasts a strong pipeline of clinical-stage candidates designed to inhibit crucial tumor growth pathways, reinforcing its position as a leader in improving therapeutic standards and patient outcomes in cancer care. Strategic partnerships within the oncology research community bolster Erasca's reputation as a vital innovator in the biopharmaceutical landscape.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?